Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Agrippal

- PMLiVE

Novartis’ ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Approximately half of those with Sjögren’s disease are thought to be undiagnosed

- PMLiVE

Novartis agrees to lower drug prices in deal with US government

In 2025, the pharma company announced a $23bn US investment commitment

- PMLiVE

Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

Around 9,000 people in the US currently live with SMA

- PMLiVE

Novartis announces plans for new US manufacturing hub

The US hub is expected to create 700 new jobs by 2030

Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

By Emily Morton-West

Amiculum

- PMLiVE

Novartis reports primary endpoint reached in phase 3 malaria trial

The treatment demonstrated non-inferiority to current standard of care

- PMLiVE

Novartis presents new positive data for rheumatic autoimmune disease treatment

Patient outcome benefits were observed in two ongoing phase 3 trials

- PMLiVE

Novartis to acquire Avidity Biosciences in deal worth $12bn

The acquisition will expand Novartis’ neuroscience pipeline

- PMLiVE

Novartis announces new data supporting MS therapy Kesimpta

The latest trial results reinforce the drug's long-term efficacy and safety profile

- PMLiVE

Osivax initiates phase 2b trial of influenza A vaccine candidate

The study aims to enrol 2,850 participants across 16 sites in Europe

- PMLiVE

A Call to Action: Bridging the Adult Immunization Divide

Over the past few years, as new diseases have emerged or reemerged, a host of new vaccines have become available while many others are in the pipeline. For older adults,...

Medscape Education

- PMLiVE

Novartis to acquire Tourmaline Bio in a deal worth $1.4bn

Novartis will gain cardiovascular treatment option pacibekitug

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links